Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX60 in Advanced Solid Tumors or Lymphoma
NCT05606380Phase 1Unknown
- Sponsor
- Henlius
- Start
- Dec 2022
- Primary completion
- Aug 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HLX60 in solid tumor and lymphoma, sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 21 days and Maximum Tolerated Dose at 21 days. Status: unknown.
02
Drugs
HLX60
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05606380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05606380.